Evaluating the orthopoxvirus type I interferon-binding molecule as a vaccine target in the vaccinia virus intranasal murine challenge model

Clinical and Vaccine Immunology

Volumn 17, Issue 11, 2010, Pages 1656-1665

  Golden, Joseph W ^a   Hooper, Jay W ^a  

^a UNITED STATES ARMY MEDICAL RESEARCH INSTITUTE OF INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4POX VACCINE; DNA VACCINE; IMMUNOGLOBULIN; INTERFERON BINDING MOLECULE; ORTHOPOXVIRUS VACCINE; UNCLASSIFIED DRUG; VIRUS PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ARTICLE; DNA IMMUNIZATION; DRUG EFFICACY; DRUG POTENCY; DRUG POTENTIATION; FEMALE; GENE GUN IMMUNIZATION; IMMUNE RESPONSE; MORTALITY; MOUSE; NONHUMAN; ORTHOPOXVIRUS; PRIORITY JOURNAL; VACCINATION; VACCINIA; VACCINIA VIRUS; VIRUS NEUTRALIZATION;

ANIMALS; ANTIGENS, VIRAL; BODY WEIGHT; MICE; MICE, INBRED BALB C; SMALLPOX VACCINE; SURVIVAL ANALYSIS; VACCINES, DNA; VACCINIA VIRUS; VIRAL PROTEINS;

EID: 78449237814     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.00235-10     Document Type: Article

References (35)

1. Adamo, J. E., C. A. Meseda, J. P. Weir, and M. J. Merchlinsky. 2009. Smallpox vaccines induce antibodies to the immunomodulatory, secreted vaccinia virus complement control protein. J. Gen. Virol. 90:2604-2608.
2. Alcami, A., J. A. Symons, and G. L. Smith. 2000. The vaccinia virus soluble alpha/beta interferon (IFN) receptor binds to the cell surface and protects cells from the antiviral effects of IFN. J. Virol. 74:11230-11239.
3. Americo, J. L., B. Moss, and P. L. Earl. 2010. Identification of wild-derived inbred mouse strains highly susceptible to monkeypox virus infection for use as small animal models. J. Virol. 84:8172-8180.
4. Bray, M. 2003. Pathogenesis and potential antiviral therapy of complications of smallpox vaccination. Antiviral Res. 58:101-114. (Pubitemid 36556213)
5. Colamonici, O. R., P. Domanski, S. M. Sweitzer, A. Larner, and R. M. Buller. 1995. Vaccinia virus B18R gene encodes a type I interferon-binding protein that blocks interferon alpha transmembrane signaling. J. Biol. Chem. 270:15974-15978.
6. Davies, D. H., M. M. McCausland, C. Valdez, D. Huynh, J. E. Hernandez, Y. Mu, S. Hirst, L. Villarreal, P. L. Felgner, and S. Crotty. 2005. Vaccinia virus H3L envelope protein is a major target of neutralizing antibodies in humans and elicits protection against lethal challenge in mice. J. Virol. 79:11724-11733.
7. Del Mar Fernandez de Marco, M., A. Alejo, P. Hudson, I. K. Damon, and A. Alcami. 2010. The highly virulent variola and monkeypox viruses express secreted inhibitors of type I interferon. FASEB J. 24:1479-1488.
8. Fang, M., H. Cheng, Z. Dai, Z. Bu, and L. J. Sigal. 2006. Immunization with a single extracellular enveloped virus protein produced in bacteria provides partial protection from a lethal orthopoxvirus infection in a natural host. Virology 345:231-243.
9. Fogg, C., S. Lustig, J. C. Whitbeck, R. J. Eisenberg, G. H. Cohen, and B. Moss. 2004. Protective immunity to vaccinia virus induced by vaccination with multiple recombinant outer membrane proteins of intracellular and extracellular virions. J. Virol. 78:10230-10237.
10. Galmiche, M. C., J. Goenaga, R. Wittek, and L. Rindisbacher. 1999. Neutralizing and protective antibodies directed against vaccinia virus envelope antigens. Virology 254:71-80. (Pubitemid 29391715)
11. Golden, J. W., and J. W. Hooper. 2008. Heterogeneity in the A33 protein impacts the cross-protective efficacy of a candidate smallpox DNA vaccine. Virology 377:19-29.
12. Golden, J. W., M. D. Josleyn, and J. W. Hooper. 2008. Targeting the vaccinia virus L1 protein to the cell surface enhances production of neutralizing antibodies. Vaccine 26:3507-3515.
13. Hashizume, S., H. Yoshizawa, M. Morita, and K. Suzuki. 1985. Properties of attenuated mutant of vaccinia virus, LC16m8, derived from Lister strain, p. 421-428. In G. V. Quainnan (ed.), Vaccinia viruses as vectors for vaccine antigens. Elsevier Science Publishing Co, Amsterdam, Netherlands.
14. Heraud, J. M., Y. Edghill-Smith, V. Ayala, I. Kalisz, J. Parrino, V. S. Kalyanaraman, J. Manischewitz, L. R. King, A. Hryniewicz, C. J. Trindade, M. Hassett, W. P. Tsai, D. Venzon, A. Nalca, M. Vaccari, P. Silvera, M. Bray, B. S. Graham, H. Golding, J. W. Hooper, and G. Franchini. 2006. Subunit recombinant vaccine protects against monkeypox. J. Immunol. 177:2552-2564.
15. Hooper, J. W., D. M. Custer, C. S. Schmaljohn, and A. L. Schmaljohn. 2000. DNA vaccination with vaccinia virus L1R and A33R genes protects mice against a lethal poxvirus challenge. Virology 266:329-339.
16. Hooper, J. W., D. M. Custer, and E. Thompson. 2003. Four-gene-combination DNA vaccine protects mice against a lethal vaccinia virus challenge and elicits appropriate antibody responses in nonhuman primates. Virology 306:181-195.
17. Hooper, J. W., A. M. Ferro, J. W. Golden, P. Silvera, J. Dudek, K. Alterson, M. Custer, B. Rivers, J. Morris, G. Owens, J. F. Smith, and K. I. Kamrud. 2009. Molecular smallpox vaccine delivered by alphavirus replicons elicits protective immunity in mice and non-human primates. Vaccine 28:494-511.
18. Hooper, J. W., J. W. Golden, A. M. Ferro, and A. D. King. 2007. Smallpox DNA vaccine delivered by novel skin electroporation device protects mice against intranasal poxvirus challenge. Vaccine 25:1814-1823.
19. Hooper, J. W., E. Thompson, C. Wilhelmsen, M. Zimmerman, M. A. Ichou, S. E. Steffen, C. S. Schmaljohn, A. L. Schmaljohn, and P. B. Jahrling. 2004. Smallpox DNA vaccine protects nonhuman primates against lethal monkeypox. J. Virol. 78:4433-4443.
20. Kenner, J., F. Cameron, C. Empig, D. V. Jobes, and M. Gurwith. 2006. LC16m8: an attenuated smallpox vaccine. Vaccine 24:7009-7022.
21. Lane, J. M., and J. Goldstein. 2003. Adverse events occurring after smallpox vaccination. Semin. Pediatr. Infect. Dis. 14:189-195.
22. Lauritzen, H. P., C. Reynet, P. Schjerling, E. Ralston, S. Thomas, H. Galbo, and T. Ploug. 2002. Gene gun bombardment-mediated expression and translocation of EGFP-tagged GLUT4 in skeletal muscle fibres in vivo. Pflugers Arch. 444:710-721.
23. McCurdy, L. H., B. D. Larkin, J. E. Martin, and B. S. Graham. 2004. Modified vaccinia Ankara: potential as an alternative smallpox vaccine. Clin. Infect. Dis. 38:1749-1753.
24. McCurdy, L. H., J. A. Rutigliano, T. R. Johnson, M. Chen, and B. S. Graham. 2004. Modified vaccinia virus Ankara immunization protects against lethal challenge with recombinant vaccinia virus expressing murine interleukin-4. J. Virol. 78:12471-12479.
25. Morikawa, S., T. Sakiyama, H. Hasegawa, M. Saijo, A. Maeda, I. Kurane, G. Maeno, J. Kimura, C. Hirama, T. Yoshida, Y. Asahi-Ozaki, T. Sata, T. Kurata, and A. Kojima. 2005. An attenuated LC16m8 smallpox vaccine: analysis of full-genome sequence and induction of immune protection. J. Virol. 79:11873-11891.
26. Moss, B., J. L. Shisler, Y. Xiang, and T. G. Senkevich. 2000. Immune-defense molecules of molluscum contagiosum virus, a human poxvirus. Trends Microbiol. 8:473-477.
27. Nguyen, D. N., P. Kim, L. Martinez-Sobrido, B. Beitzel, A. Garcia-Sastre, R. Langer, and D. G. Anderson. 2009. A novel high-throughput cell-based method for integrated quantification of type I interferons and in vitro screening of immunostimulatory RNA drug delivery. Biotechnol. Bioeng. 103:664-675.
28. Plotkin, S. A. 2010. Correlates of protection induced by vaccination. Clin. Vaccine Immunol. 17:1055-1065.
29. Sakhatskyy, P., S. Wang, T. H. Chou, and S. Lu. 2006. Immunogenicity and protection efficacy of monovalent and polyvalent poxvirus vaccines that include the D8 antigen. Virology 355:164-174. (Pubitemid 44692776)
30. Schmaljohn, C., L. Vanderzanden, M. Bray, D. Custer, B. Meyer, D. Li, C. Rossi, D. Fuller, J. Fuller, J. Haynes, and J. Huggins. 1997. Naked DNA vaccines expressing the prM and E genes of Russian spring summer encephalitis virus and Central European encephalitis virus protect mice from homologous and heterologous challenge. J. Virol. 71:9563-9569. (Pubitemid 27492403)
31. Seet, B. T., J. B. Johnston, C. R. Brunetti, J. W. Barrett, H. Everett, C. Cameron, J. Sypula, S. H. Nazarian, A. Lucas, and G. McFadden. 2003. Poxviruses and immune evasion. Annu. Rev. Immunol. 21:377-423.
32. Symons, J. A., A. Alcami, and G. L. Smith. 1995. Vaccinia virus encodes a soluble type I interferon receptor of novel structure and broad species specificity. Cell 81:551-560.
33. Werden, S. J., and G. McFadden. 2008. The role of cell signaling in poxvirus tropism: the case of the M-T5 host range protein of myxoma virus. Biochim. Biophys. Acta 1784:228-237.
34. Xiao, Y., L. Aldaz-Carroll, A. M. Ortiz, J. C. Whitbeck, E. Alexander, H. Lou, H. L. Davis, T. J. Braciale, R. J. Eisenberg, G. H. Cohen, and S. N. Isaacs. 2007. A protein-based smallpox vaccine protects mice from vaccinia and ectromelia virus challenges when given as a prime and single boost. Vaccine 25:1214-1224.
35. Xu, R. H., M. Cohen, Y. Tang, E. Lazear, J. C. Whitbeck, R. J. Eisenberg, G. H. Cohen, and L. J. Sigal. 2008. The orthopoxvirus type I IFN binding protein is essential for virulence and an effective target for vaccination. J. Exp. Med. 205:981-992.